Ccx 354-c (DrugBank: CCX-354)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01027728 (ClinicalTrials.gov) | December 2009 | 7/12/2009 | Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis | A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: CCX 354-C | ChemoCentryx | NULL | Completed | 18 Years | 75 Years | Both | 24 | Phase 1;Phase 2 | Belgium;Romania |